8 дек. 2023 г. · The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years ...

21 февр. 2024 г. · CASGEVY indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso occlusive crises (VOCs).

16 янв. 2024 г. · Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia · Low levels ...

8 дек. 2023 г. · “CASGEVY's approval by the FDA is momentous: it is the first CRISPR-based gene-editing therapy to be approved in the U.S.

16 янв. 2024 г. · Vertex and CRISPR have scored an FDA approval for their gene therapy Casgevy to treat transfusion dependent beta-thalassemia (TDT).

16 янв. 2024 г. · CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of ...

16 янв. 2024 г. · Aside from FDA approval, CASGEVY™ has gained approval for transfusion-dependent thalassaemia by the UK's Medicines & Healthcare products ...

17 янв. 2024 г. · The FDA has approved Vertex and CRISPR's gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare ...

16 янв. 2024 г. · Vertex Pharmaceuticals and CRISPR Therapeutics have secured another FDA approval for their Casgevy Cas9 gene-edited cell therapy, ...